Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.46 |
| ▸ | SLC6A7 | Q99884 | 2/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1448772 | 0.87 | ALOX5 (0.49) | GPR119CHRM4KMT2ASLC6A5 | |
| SCHEMBL1449656 | 0.83 | GPR119 (0.47) | GPR119CHRM4SLC6A7MEN1KMT2A | |
| SCHEMBL1447826 | 0.77 | GPR119 (0.73) | GPR119 | |
| SCHEMBL21551278 | 0.77 | GPR119 (0.59) | GPR119CHRM4SLC6A7 | |
| SCHEMBL22519008 | 0.73 | CHRM1 (0.46) | GPR119CHRM4SLC6A7 | |
| SCHEMBL25383375 | 0.72 | SLC6A7 (0.45) | CHRM4SLC6A7MEN1KMT2AHSD17B10 | |
| SCHEMBL21564435 | 0.72 | GPR119 (0.78) | GPR119 | |
| SCHEMBL28539423 | 0.72 | GPR119 (0.78) | GPR119 | |
| SCHEMBL5222720 | 0.70 | HDAC1 (0.48) | CHRM4SLC6A7 | |
| SCHEMBL12820493 | 0.70 | GPR119 (0.68) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065706-A1 | Therapeutic Agents 812 | ASTRAZENECA AB (SE) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065706-A1 | Therapeutic Agents 812 | GPR119, GPR84, GPR132 | GPR119 1/4885CHRM4 1168/4885SLC6A7 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.